July 1, 2026
Experts confirm ADT+ARPI is standard for mCSPC in elderly/frail patients, using real-world data to bridge the gap from clinical trials.
June 30, 2026
Dr. Claire Harrison discusses the INDEPENDENCE trial, where luspatercept narrowly missed its primary endpoint for myelofibrosis anemia but showed meaningful benefit.
Dr. O'Malley discusses biomarker-driven strategies and ADC sequencing to address the high unmet need in platinum-resistant ovarian cancer.
June 29, 2026
FDA approves an all-oral decitabine/cedazuridine plus venetoclax for AML, improving patient quality of life with comparable efficacy to IV therapy.
June 26, 2026
Experts discuss translating biomarker insights (MMR, p53, HER2, POLE) into personalized endometrial cancer treatment and staging.
June 22, 2026
FDA approves a new orally disintegrating nilotinib tablet for CML, improving dosing consistency, safety, and patient convenience.
June 19, 2026
KRAS-directed therapy is revolutionizing pancreatic cancer, with pan-RAS and allele-specific inhibitors showing promise over traditional chemo.
June 18, 2026
Dr. Haverkos on cutaneous T-cell lymphoma (CTCL) treatment: tailoring therapy by stage and managing mogamulizumab-associated rash.
June 15, 2026
Experts discuss oral SERDs in HR+/HER2– breast cancer, debating ctDNA-guided therapy vs. clinical progression based on SERENA-6 & Avera data.
June 10, 2026
Dr. Joshua Richter previews key myeloma data at EHA 2026, highlighting immunotherapy combinations, sequencing challenges, and in vivo CAR-Ts.
June 8, 2026
RASolute 302 trial: Daraxon-rasib doubles survival in metastatic pancreatic cancer, setting a new second-line standard of care. A game-changer.
June 5, 2026
Molecular profiling is revolutionizing glioma treatment, with targeted therapies like vorasidenib and tovorafenib improving outcomes in adults & children.
June 1, 2026
Experts discuss multidisciplinary skin cancer care, from sun safety and chemoprophylaxis to advanced radiation and systemic therapies.
May 28, 2026
Experts discuss how in-house NGS for NSCLC improves turnaround times, tissue stewardship, and multidisciplinary care for precision oncology.
May 27, 2026
Cervical cancer care is evolving with immunotherapy and ADCs, but prevention via widespread, early HPV vaccination remains the critical priority.
May 26, 2026
Dr. Jacob Sands discusses the new era in SCLC care, highlighting tarlatumab's role, emerging molecular subtyping, and updated NCCN guidelines.
May 20, 2026
Experts discuss ESR1 mutation testing, ctDNA's role, and why the positive but contested Serena VI trial is key for precision oncology's future.
May 13, 2026
Dr. Enzinger discusses esophageal cancer: accurate staging pitfalls, the evolving role of surgery, and emerging targeted and non-operative therapies.
FDA's full approval of Brexu-Cel for Mantle Cell Lymphoma marks a paradigm shift. Learn about its efficacy and post-treatment management.
May 12, 2026
A 10-year metastatic breast cancer survivor discusses the power of self-advocacy, community, and humor in navigating diagnosis and treatment.
May 8, 2026
Biomarker-directed therapies for HER2, Claudin-18.2, BRAF, and KRAS are transforming GI oncology, demanding upfront testing for personalized care.
May 6, 2026
Experts discuss NSCLC cases (KRAS G12C, ROS1), highlighting next-gen sequencing, reflex testing, and emerging targeted therapies.
May 4, 2026
Metastatic bladder cancer treatment is revolutionized by frontline EV-PEMBRO, which doubles survival. Learn the new paradigm and key toxicities.
May 1, 2026
KRAS inhibitors, especially pan-RAS agent daraxoracib, show major promise in pancreatic cancer, with trials set to redefine treatment standards.
FES-PET/CT is transforming lobular breast cancer imaging, detecting more disease than traditional scans and altering treatment plans for many.
April 30, 2026
Dr. Alissa Cooper on Tarlatumab's impact on relapsed SCLC, real-world sequencing challenges, and the need for better care coordination.
April 29, 2026
Experts discuss diagnostic and treatment breakthroughs for extrapulmonary NECs, focusing on biomarkers and promising novel targets like DLL3.
April 28, 2026
Experts discuss GLP-1 agonists in breast cancer: reviewing current data, patient outcomes, ongoing trials, and clinical recommendations.
Experts discuss using ctDNA to detect ESR1 mutations and integrating next-gen oral SERDs to combat endocrine resistance in HR+/HER2- breast cancer.
April 27, 2026
Experts discuss menin inhibitors for acute leukemia, covering mechanism, clinical data, adverse event management, and promising combination therapies.
April 24, 2026
Targeting the RAS/MAP kinase pathway in gynecologic cancers is advancing with new drugs like avutometinib and promising direct RAS inhibitors.
Experts discuss personalizing TNBC care with immunotherapy and ADCs, reviewing key trials and the evolving early-stage and metastatic landscape.
April 23, 2026
Experts discuss pivotal trials for HR+/HER2- breast cancer, focusing on oral SERDs and PI3K/AKT inhibitors post-CDK4/6 progression.
April 21, 2026
Experts discuss translating evidence on oral SERDs for HR+/HER2- breast cancer, focusing on biomarker-driven sequencing for ESR1/PIK3CA mutations.
April 20, 2026
Experts discuss personalizing adjuvant therapy in high-risk HR+/HER2- breast cancer, covering chemo, CDK4/6i, PARP inhibitors, and IO.
April 17, 2026
Experts discuss immunotherapy in head & neck cancer, highlighting neoadjuvant pembrolizumab as a new standard and ongoing chemoradiation trials.
April 14, 2026
Experts discuss using genomic assays to de-escalate chemo and CDK4/6 inhibitors to intensify therapy in early HR+/HER2- breast cancer.
April 10, 2026
Experts discuss PATINA & HER2-CLIMB-05 trials, redefining maintenance therapy for HER2+ metastatic breast cancer after induction treatment.
April 7, 2026
Indirect comparison in CLL shows continuous zanubrutinib may offer longer remission than fixed-duration acalabrutinib plus venetoclax.
Experts debate TD-XD for early HER2+ breast cancer: neoadjuvant for high tumor response vs. post-neoadjuvant for proven survival benefit.
April 3, 2026
Experts discuss mainstreaming genetic testing in breast cancer to guide personalized surgical decisions and targeted therapies for better outcomes.
April 2, 2026
Experts discuss holistic breast cancer survivorship, linking endocrine therapy to metabolic health, lifestyle interventions, and the role of GLP-1 drugs.
March 31, 2026
FDA's full approval of Rucaparib for BRCA+ mCRPC, based on TRITON3, positions it as a superior pre-chemotherapy option for this population.
Financial toxicity in gynecologic oncology is pervasive, impacting patient outcomes. Experts discuss its drivers and a navigation program to help.
Experts discuss evolving chronic GVHD care, from PTCI and ORCA-T in prophylaxis to challenges in first-line and options for refractory disease.
SCLC care varies widely. Experts call for broader trial eligibility, biomarker development, and community prep for new therapies like ADCs.
March 30, 2026
FDA approves zongertinib for HER2 TKD-mutated NSCLC, a pivotal shift to upfront, biomarker-driven care with high efficacy and a manageable profile.
Dr. Misty Shields discusses the urgent, multidisciplinary care needed for Small Cell Lung Cancer and the challenges of integrating new therapies.
March 27, 2026
Experts discuss precision oncology in advanced NSCLC, covering targeted therapies for KRAS, NRG1, MET, and ROS1 mutations and testing.
Experts discuss new RAS inhibitors, the critical need for early biomarker testing in GI cancers, and using targeted therapies upfront.
March 26, 2026
Drs. McCann and Nunnery analyze transformative T-DXd trials (DB-11, DB-05) for early HER2+ breast cancer, weighing new efficacy against ILD risks.
March 25, 2026
Dr. Jae Park discusses CAR T-cell therapy for ALL, focusing on Obicell and Brexacel, the critical need for early use, and future directions.
Real-world data validates ctDNA monitoring and confirms pemigatinib's efficacy for FGFR2-altered cholangiocarcinoma.
March 23, 2026
ASCO GU 2026 recap: Practice-changing data in bladder (EV+Pembro), RCC (Belzutifan combos), prostate (PCEC-3), & a non-chemo first for GCTs.
March 20, 2026
In GIST, ctDNA testing at progression is crucial to detect resistance mutations and guide TKI sequencing for improved patient outcomes.
Dr. Wendy Stock discusses new ASH guidelines for AYA-ALL, highlighting the shift to pediatric-inspired therapies to improve survival outcomes.
March 18, 2026
A chemo-free combo of blinatumomab & ponatinib shows 95% remission in Ph+ B-ALL, enabling transplant-free survival with a favorable safety profile.
March 17, 2026
Experts dissect data on menin inhibitors for KMT2A & NPM1 AML, covering efficacy, safety, and their evolving role in patient care.
March 13, 2026
TAMP delivers high-dose chemo directly to pancreatic tumors, bypassing systemic resistance. Early trials show improved survival & lower toxicity.
Experts discuss new trial data for gastric & esophageal cancers, from perioperative DFLOT to targeted therapies and the emerging role of ctDNA.
March 11, 2026
Dr. Sonali Smith discusses CAR T-cell therapy for solid tumors, the critical role of clinical trials, and the rise of cancer in young adults.
March 10, 2026
Experts discuss post-TKI sequencing in EGFR+ NSCLC, emphasizing repeat biopsy for guiding MET targeting and adopting new treatment modalities.
March 8, 2026
Leading oncologists discuss navigating career transitions, work-life harmony, and the critical power of sponsorship for women in medicine.
March 6, 2026
FDA approves Daratumumab+VRd for transplant-ineligible myeloma, boosting response depth and survival based on the Phase III CEPHEUS trial.
Experts discuss breakthroughs in BCG-unresponsive NMIBC, detailing new intravesical and systemic therapies for personalized patient care.
March 5, 2026
TROP2-targeted ADCs like DatoDXD are reshaping lung cancer therapy, offering new options post-chemo but requiring careful toxicity management.
March 3, 2026
Experts review key trial data for immunotherapy and EGFR inhibitors in resectable early-stage NSCLC, optimizing patient treatment pathways.
February 27, 2026
SCLC enters a new era with immunotherapy & targeted therapies like tarlatumab. Dr. Chiang discusses biomarker strategies & holistic patient care.
Experts discuss breast imaging advances, highlighting FES PET-CT's unique role in diagnosing and managing ER+ and lobular breast cancer.
Experts discuss rising anal cancer rates and the PODIUM 303 study, establishing carboplatin/paclitaxel + retafanilumab as the new standard.
February 26, 2026
CheckMate 9LA 6-year data confirm durable survival in metastatic NSCLC with nivo/ipi/chemo, especially in PD-L1 negative & squamous types.
Pumitamig, a PD-L1/VEGF-A bispecific, shows high efficacy in TNBC, offering a new immunotherapy option for PD-L1 negative patients.
Dr. Rashmi Chugh discusses varegacestat, a promising gamma-secretase inhibitor for desmoid tumors, highlighting positive Phase 3 data.
Experts discuss bispecific antibodies in solid tumors, detailing PD-1/CTLA-4, VEGF/PD-1, and DLL-3 agents and their promising clinical data.
February 25, 2026
Evolving standards in cervical cancer care now include immunotherapy and emerging ADCs, redefining treatment for both locally advanced and metastatic disease.
Experts discuss frontline metastatic pancreatic cancer care, balancing NALIRIFOX/FOLFIRINOX, prioritizing quality of life, and championing trials.
Dr. Gesiotto on optimizing ponatinib dosing in CML, the shift to potent frontline TKIs, and the future of personalized, genetically-driven therapy.
Dr. Borghaei shares his journey from Iran to leading thoracic oncology, discussing medical evolution, mentorship, and the human touch in care.
February 24, 2026
ASCO GU 2026 Preview: Experts discuss key trials in prostate, bladder, and RCC, focusing on novel combinations, ctDNA, and radioligands.
February 19, 2026
Experts discuss chondrosarcoma diagnosis, the central role of surgery, and emerging targeted therapies like IDH1 inhibitors and DR5 agonists.
Subcutaneous amivantamab for EGFR+ NSCLC is a win-win, cutting chair time and infusion reactions with potentially better efficacy.
February 18, 2026
Experts discuss epithelioid sarcoma, covering diagnostic delays, multidisciplinary care, and treatment sequencing with chemotherapy vs. tazometastat.
February 13, 2026
In Ph+ ALL, ponatinib is the preferred frontline TKI, often in chemotherapy-free regimens with blinatumomab for deeper, durable responses.
February 11, 2026
Third-line mCRC treatment shifts from aggressive response to stabilization, guided by patient status, prior toxicities & molecular retesting.
Experts decode mesothelioma diagnosis and treatment, comparing nivolumab/ipilimumab vs. chemo-immunotherapy based on histology and patient factors.
February 10, 2026
Targeted therapies like gerodestrin (Ladera study) are showing superiority in ER+ breast cancer, driving a shift toward personalized care.
February 5, 2026
Rethinking dose intensity: Lower upfront Enfortumab Vedotin doses for urothelial cancer may cut toxicity without impacting overall survival.
February 4, 2026
ASCO's 2026 president-elect, Dr. Deb Schrag, outlines priorities for oncology: democratizing research, embracing AI, and ensuring an equitable workforce.
January 31, 2026
Experts discuss the evolving CSCC paradigm, highlighting neoadjuvant immunotherapy, multidisciplinary teamwork, and personalized medicine.
The ASCENT-07 trial for Sacituzumab Govitecan failed to improve first-line outcomes in HR+ breast cancer, maintaining standard chemo's role.
Pirtobrutinib's FDA approval in relapsed/refractory CLL expands second-line treatment options, emphasizing personalized sequencing and safety.
January 30, 2026
Early, reflex biomarker testing is crucial in NSCLC. Pathologist-led, coordinated care is key to reducing delays and optimizing treatment.
Sub-Q Isatuximab via an on-body device is non-inferior to IV for myeloma, proving effective across all body weights and enabling home care.
Experts discuss pivotal trials for metastatic TNBC, detailing the impact of TROP2 ADCs, ICIs, and PARP inhibitors on evolving treatment.
Long-term epcoritamab data show durable responses (>4 years) and confirmed safety in LBCL, supporting its use as a curative third-line option.
Experts outline proactive, multidisciplinary strategies for managing diarrhea, hyperglycemia, and rash from PI3K/AKT inhibitors in breast cancer.
January 29, 2026
Dr. Bardia discusses the Phase III ELEGANT trial, evaluating elacestrant vs. standard endocrine therapy in high-risk, ER+/HER2- early breast cancer.
Beyond JAK inhibitors: Experts discuss novel targeted agents like CALR and JAK2V617F inhibitors poised to reshape MPN treatment paradigms.
Experts discuss managing high-dose methotrexate-induced acute kidney injury, highlighting glucarpidase for rapid clearance and improved recovery.
January 28, 2026
Experts discuss immunotherapy's new role in GYN cancers, from the B96 trial in ovarian cancer to novel cell therapies on the horizon.
January 26, 2026
Experts discuss integrating practice-changing data from DESTINY and PATINA trials, focusing on TDXD's expanding role in breast cancer.
January 22, 2026
Experts discuss ctDNA-guided therapy for HR+/HER2- MBC, focusing on ESR1 mutations and the expanding arsenal of next-gen endocrine agents.
January 21, 2026
Experts discuss transforming SCLC care with immunotherapy (ADRIATIC trial) in limited stage & new agents like tarlatumab for extensive stage.
Experts discuss the rise of RAS inhibitors, detailing pivotal data in lung, pancreatic, and GYN cancers transforming this undruggable target.
January 20, 2026
Dr. Garcia-Manero discusses the GLORIA-IV trial, evaluating lisaftoclax plus azacitidine for higher-risk MDS as a potential new standard of care.
Experts discuss optimizing HR+/HER2- metastatic breast cancer care with CDK4/6i, targeted agents, and novel antibody-drug conjugates.
Experts discuss PSMA-targeted radioligand therapy, from advanced PET imaging diagnostics to pivotal clinical trial data and access barriers.
January 19, 2026
Experts debate adjuvant CDK4/6i, PARPi, & ICIs in early-stage HR+/HER2- breast cancer, focusing on MONARCH-E, NATALY, & OlympiA trial data.
January 16, 2026
Dr. Rahul Banerjee explains how emerging CELMoDs are a new drug class set to replace IMiDs in myeloma, offering superior efficacy and safety.
Experts discuss personalizing HER2+ metastatic breast cancer therapy with data from PATINA, HER2CLIMB-05, and strategies for brain mets.
January 15, 2026
FDA approves Epcoritamab+R² for relapsed follicular lymphoma, establishing a new, highly effective, chemo-free standard based on Epcor FL1 data.
January 9, 2026
FDA approves belantamab mafodotin for myeloma, a new community-based option. Key challenges: ocular toxicity management & sequencing with CAR-T.
January 7, 2026
COMPETE trial: 177Lu-Edotreotide PRRT shows a 10-month progression-free survival benefit over everolimus in metastatic GEP-NETs.
January 5, 2026
Experts discuss de-escalating breast cancer therapy, emphasizing collaboration between surgery and radiation for personalized, less invasive care.
December 31, 2025
Experts discuss the evolving CLL treatment landscape, balancing fixed vs. continuous therapy, patient preference, and sequencing new BTK inhibitors.
FDA-approved Enfortumab Vedotin/Pembrolizumab (EVP) redefines MIBC care, showing huge survival benefits for cisplatin-ineligible patients.
December 29, 2025
ADAURA, LAURA & NeoADURA trials expand osimertinib's role in perioperative EGFR-mutated NSCLC, making early biomarker testing essential.
December 25, 2025
Experts discuss advanced MRI & PET imaging for gliomas, highlighting how FET PET can clarify ambiguous cases of progression vs. pseudoprogression.
December 22, 2025
Dr. Jason Mouabbi discusses ctDNA's transformative role in breast cancer, from screening to predicting recurrence and guiding treatment.
December 18, 2025
Gut microbiome profiling reveals that butyrate loss after stem cell transplant worsens multiple myeloma outcomes, highlighting diet's critical role.
December 17, 2025
Experts discuss Sigvotatug Vedotin, an ADC targeting the highly prevalent IB6 biomarker in NSCLC, as a potential new second-line standard of care.
ASH 2025 update: Pirtobrutinib shows superior PFS vs. chemoimmunotherapy in frontline CLL, but its place among modern therapies is debated.
